Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephanie Molden

Obstetrics & Gynecology Newtown, PA Medical Doctor

NPI 1538193156 CMS profile 69782

760 Newtown Yardley Rd, Suite 115, Newtown, PA 18940

Open in the dashboard

General payments

$92,184

250 records reported · program years 2019–2025

Research payments

$41,073

Paid to them · 26 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$55,722 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Stephanie Molden of Newtown, PA is reported in the CMS Open Payments database as having received $92,184 across 250 general payments and $41,073 in research payments paid to them. Separately, studies naming them as principal investigator received $55,722 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,591 29
2024 General $4,582 20
2023 General $12,256 38
2023 Research $1,239 2
2022 General $4,511 44
2022 Research $10,967 2
2021 General $4,596 36
2021 Research $4,143 4
2020 General $3,455 17
2020 Research $9,425 8
2019 General $46,192 66
2019 Research $15,300 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Molden
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Stephanie Molden were reported at $16,591. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Stephanie Molden Obstetrics & Gynecology median Middle half National median
2019 $46,192 $172 $62–$391 $163
2020 $3,455 $94 $36–$222 $114
2021 $4,596 $136 $42–$369 $132
2022 $4,511 $160 $50–$433 $149
2023 $12,256 $169 $56–$423 $160
2024 $4,582 $152 $50–$371 $164
2025 $16,591 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $76,580 130 payments
  2. Caldera Medical, Inc $5,985 30 payments
  3. Contura, Inc. $3,235 5 payments
  4. FEMSelect Inc. $2,000 1 payment
  5. Boston Scientific Corporation $1,579 10 payments
  6. Axonics Modulation Technologies, Inc. $469 11 payments
  7. RTI Surgical, Inc. $450 1 payment
  8. Sumitomo Pharma America, Inc. $326 13 payments
  9. Becton, Dickinson and Company $255 1 payment
  10. Escala Medical Inc. $181 2 payments
  11. Other $1,124 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $35,116 17 payments
  2. Education $31,832 14 payments
  3. Travel and Lodging $15,399 11 payments
  4. Food and Beverage $8,166 198 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $900 2 payments
  6. Gift $589 6 payments
  7. Entertainment $182 2 payments
Products named General payments · program years 2019–2025
  1. ALTIS Female Incontinence $42,633 33 payments
  2. Altis Women's Health $31,863 48 payments
  3. Desara $5,772 29 payments
  4. Bulkamid $3,235 5 payments
  5. NEUGUIDE $2,000 1 payment
  6. General - Female SUI $900 2 payments
  7. GEMTESA $454 20 payments
  8. Coloplast AXIS $450 1 payment
  9. General Therapies $400 1 payment
  10. Axonics $398 8 payments
  11. Other $1,942 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $41,073 26 payments

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

403

Median for Obstetrics & Gynecology: 65

Drug cost

$121,960

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

49.9%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 75 $56,908
Myrbetriq Mirabegron Brand 77 $45,160
Estradiol Generic 100 $6,296
Premarin Estrogens, Conjugated Brand 12 $5,531
Methenamine Hippurate Generic 50 $4,040
Trospium Chloride Er Trospium Chloride Brand 15 $2,511
Solifenacin Succinate Generic 19 $596
Clobetasol Propionate Generic 13 $497
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 22 $363
Ciprofloxacin Hcl Generic 20 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$343,471

Of which drugs: $7,962

Medicare patients

479

Average age 74

Services billed

25,411

479 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 54%
Osteoporosis 32%
Depression 21%
Diabetes 19%
Ischemic heart disease 18%
Cancer 16%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 91 6,232 $4,715
Injection, heparin sodium, per 1000 units J1644 Office 91 13,500 $2,552
Injection, hydrocortisone sodium succinate, up to 100 mg J1720 Office 28 34 $484
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 43 107 $212

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $103
$103 75 —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

276 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record